ATE427354T1 - Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden - Google Patents

Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden

Info

Publication number: ATE427354T1
Authority: AT; Austria
Prior art keywords: mage; hla class; molecules; polypeptides presented; peptides
Prior art date: 1998-10-05

Application number

AT99970121T

Other languages

English (en)

Inventor

Pascal Chaux

Vincent Stroobant

Thierry Boon-Falleur

Der Bruggen Pierre Van

Erwin Schultz

Snick Jacques Van

Bernard Lethe

Kris Thielemans

Jurgen Corthals

Carlo Heirman

Original Assignee

Ludwig Inst For Cancer Res Ltd

Univ Bruxelles

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-05

Filing date

1999-09-15

Publication date

2009-04-15

1999-09-15 Application filed by Ludwig Inst For Cancer Res Ltd, Univ Bruxelles filed Critical Ludwig Inst For Cancer Res Ltd

2009-04-15 Application granted granted Critical

2009-04-15 Publication of ATE427354T1 publication Critical patent/ATE427354T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
108090000623 proteins and genes Proteins 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT99970121T 1998-10-05 1999-09-15 Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden ATE427354T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/166,448 US6291430B1 (en)	1997-09-12	1998-10-05	Mage-3 peptides presented by HLA class II molecules

Publications (1)

Publication Number	Publication Date
ATE427354T1 true ATE427354T1 (de)	2009-04-15

Family

ID=22603350

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99970121T ATE427354T1 (de)	1998-10-05	1999-09-15	Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden

Country Status (7)

Country	Link
US (3)	US6291430B1 (de)
EP (1)	EP1119623B1 (de)
JP (1)	JP4102027B2 (de)
AT (1)	ATE427354T1 (de)
AU (1)	AU772720B2 (de)
DE (1)	DE69940671D1 (de)
WO (1)	WO2000020581A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE272113T1 (de) *	1994-02-16	2004-08-15	Crucell Holland Bv	Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
US20040156861A1 (en) *	1996-07-11	2004-08-12	Figdor Carl Gustav	Melanoma associated peptide analogues and vaccines against melanoma
US7888100B2 (en) *	1996-10-03	2011-02-15	Memorial Sloan-Kettering Cancer Research	Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
PT1053325E (pt) *	1998-02-05	2006-05-31	Glaxosmithkline Biolog Sa	Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
US20030138808A1 (en) *	1998-02-19	2003-07-24	Simard John J.L.	Expression vectors encoding epitopes of target-associated antigens
IT1312568B1 (it) *	1999-05-21	2002-04-22	Genera Spa	Peptidi immunogenici e loro uso.
US7429639B2 (en)	1999-09-29	2008-09-30	Ludwig Institute For Cancer Research	SSX-2 peptides presented by HLA class II molecules
US20030215425A1 (en) *	2001-12-07	2003-11-20	Simard John J. L.	Epitope synchronization in antigen presenting cells
DK1282702T3 (da) *	2000-05-10	2007-04-02	Sanofi Pasteur Ltd	Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) *	2001-08-17	2003-06-19	Aventis Pasteur, Ltd.	Immunogenic targets for melanoma
US20030232013A1 (en) *	2002-02-22	2003-12-18	Gary Sieckman	Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
DE10213493A1 (de) *	2002-03-26	2003-10-16	Stephan Grabbe	Verfahren zur Aktivierung von dendritischen Zellen
FR2837837B1 (fr)	2002-03-28	2006-09-29	Roussy Inst Gustave	Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
US20030206916A1 (en) *	2002-05-03	2003-11-06	Rush-Presbyterian-St. Luke's Medical Center	Immunogenic peptides
US7041502B2 (en) *	2002-06-05	2006-05-09	Ludwig Institute For Cancer Research	Isolated peptides which bind to HLA-B18 molecules and uses thereof
WO2005007673A2 (en) *	2003-07-03	2005-01-27	Rush University Medical Center	Immunogenic peptides
DE602004031116D1 (de)	2003-07-22	2011-03-03	Ludwig Inst For Cancer Res New York	Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide
GB0323968D0 (en) *	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
ATE552011T1 (de) *	2003-10-15	2012-04-15	Ist Superiore Sanita	Kolorektal-karzinom-antigen
US20070154889A1 (en) *	2004-06-25	2007-07-05	Veridex, Llc	Methods and reagents for the detection of melanoma
US20090169573A1 (en) *	2004-10-20	2009-07-02	Erwin Schultz	T-Cell Stimulatory Peptides From The Melanoma-Associated Chondroitin Sulfate Proteoglycan And Their Use
CA2523032A1 (en)	2005-10-07	2007-04-07	Immunovaccine Technologies Inc.	Vaccines for cancer therapy
WO2008053573A1 (fr)	2006-10-30	2008-05-08	National University Corporation Hokkaido University	Remède pour néoplasme malin
CA2699853A1 (en)	2007-09-17	2009-03-26	Oncomethylome Sciences Sa	Improved detection of mage-a expression
CA2700808C (en)	2007-09-27	2017-11-14	Immunovaccine Technologies Inc.	Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) *	2007-10-03	2010-08-19	Immunovaccine Technologies, Inc	Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2524699T3 (es) *	2008-06-05	2014-12-11	Immunovaccine Technologies Inc.	Composiciones que comprenden liposomas, un antígeno, un polinucleótido y un vehículo que comprende una fase continua de una sustancia hidrófoba
US20140050780A1 (en)	2010-12-23	2014-02-20	Ludwig Institute For Cancer Research Ltd.	Liposomal formulation of nonglycosidic ceramides and uses thereof
JP6240077B2 (ja)	2011-10-06	2017-11-29	イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅＴｅｃｈｎｏｌｏｇｉｅｓＩｎｃ．	Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
US9365496B2 (en)	2011-11-30	2016-06-14	Ludwig Institute For Cancer Research	iNKT cell modulators and methods of using the same
WO2013134365A1 (en)	2012-03-08	2013-09-12	Ludwig Institute For Cancer Research Ltd	TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
US10259626B2 (en)	2012-03-08	2019-04-16	Selig Sealing Products, Inc.	Container sealing member with protected security component and removal tab
US9895549B2 (en)	2012-11-06	2018-02-20	The Florida International University Board Of Trustees	On-demand drug release using magneto-electric nanoparticles
WO2014074584A1 (en)	2012-11-06	2014-05-15	Sakhrat Khizroev	On-demand drug release using magneto-electric nanoparticles
JP6313478B2 (ja) *	2014-05-30	2018-04-18	アカデミアシニカＡｃａｄｅｍｉａＳｉｎｉｃａ	Ｍａｇｅ−ａ３ペプチド標的アプタマー及びその使用
WO2016094309A1 (en)	2014-12-10	2016-06-16	Myosotis	Inhibition of tnf signaling in cancer immunotherapy
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2983924T3 (es) *	2015-03-27	2024-10-28	Immatics Biotechnologies Gmbh	Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
US10723793B2 (en)	2015-06-12	2020-07-28	Ludwig Institute For Cancer Research, Ltd.	TGF-β3 specific antibodies and methods and uses thereof
IL274572B2 (en)	2015-07-16	2024-01-01	Biolinerx Ltd	Compositions and methods for treating cancer
GB201519340D0 (en)	2015-11-02	2015-12-16	Cambridge Entpr Ltd	Methods of T-lymphocyte expansion
GB201519481D0 (en)	2015-11-04	2015-12-16	Cancer Rec Tech Ltd	Immunomodulatory antibodies
GB201616238D0 (en)	2016-09-23	2016-11-09	Adaptimmune Ltd	Modified T cells
PT3565828T (pt)	2017-01-05	2022-02-08	Kahr Medical Ltd	Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
GB201700345D0 (en)	2017-01-09	2017-02-22	F-Star Beta Ltd	Conditional agonists of immune responses
IL250916A0 (en)	2017-03-02	2017-06-29	Geiger Benjamin	Methods for growing t cells in culture and their use
WO2018226931A1 (en) *	2017-06-07	2018-12-13	David Weiner	Mage-a vaccines and methods of treatment using the same
WO2019006003A1 (en)	2017-06-27	2019-01-03	The Trustees Of Princeton University	COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
GB201713078D0 (en)	2017-08-15	2017-09-27	Adaptimmune Ltd	T Cell Modification
CN111801415A (zh)	2017-11-06	2020-10-20	路德维格癌症研究院	扩增淋巴细胞的方法
JP2021515588A (ja)	2018-01-26	2021-06-24	ケンブリッジエンタープライズリミティッド	ペプチド交換蛋白質
US12134638B2 (en)	2018-07-11	2024-11-05	Kahr Medical Ltd.	SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
GB201811410D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	OX40 Binding molecules
GB201811408D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	CD137 Binding Molecules
GB201811404D0 (en)	2018-07-12	2018-08-29	F Star Beta Ltd	Anti-CD137 Antibodies
US12606816B2 (en) *	2018-07-31	2026-04-21	Janux Therapeutics, Inc.	Inhibitory T cell receptor peptides and discovery methods
CN109081873B (zh) *	2018-08-10	2022-04-22	固安鼎泰海规生物科技有限公司	一种抗肿瘤重组nmm融合抗原质粒dna疫苗
CN108949662A (zh) *	2018-08-10	2018-12-07	固安鼎泰海规生物科技有限公司	一种用于裸质粒pSFVK1-NMM生产的大肠杆菌发酵培养基
WO2020041662A1 (en)	2018-08-24	2020-02-27	The Trustees Of Princeton University	Immunotherapy with metabolic enzyme expression
CN113613726B (zh)	2018-11-05	2025-07-15	路德维格癌症研究所有限公司	人源化和变体TGF-β3特异性抗体及其方法和用途
WO2020095113A1 (en)	2018-11-05	2020-05-14	Ludwig Institute For Cancer Research Ltd	Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
GB201820444D0 (en)	2018-12-14	2019-01-30	Adaptimmune Ltd	Marker for T cell expansion
US20220267409A1 (en)	2019-07-11	2022-08-25	Kahr Medical Ltd.	Heterodimers and methods of use thereof
GB201911954D0 (en)	2019-08-20	2019-10-02	Adaptimmune Ltd	Lentiviral transduction methods
US20230048361A1 (en)	2019-12-31	2023-02-16	Kahr Medical Ltd.	Methods of culturing t cells and uses of same
WO2021137231A1 (en)	2019-12-31	2021-07-08	Kahr Medical Ltd.	Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en)	2020-08-09	2022-03-01	Yeda Res & Dev	T cell receptor unique to mage-a1 and its uses
CN117157318A (zh)	2020-12-30	2023-12-01	免疫治疗有限公司	抗hvem抗体
US20230132140A1 (en) *	2021-09-15	2023-04-27	Celloram Inc.	Method of treating cancer
CA3251359A1 (en)	2022-05-17	2023-11-23	École Polytechnique Fédérale de Lausanne	BIOSENSORS DESIGNED FOR ENHANCED T LYMPHOCYTE THERAPY
GB202303250D0 (en)	2023-03-06	2023-04-19	King S College London	Method and compounds
WO2024228167A1 (en)	2023-05-03	2024-11-07	Iox Therapeutics Inc.	Inkt cell modulator liposomal compositions and methods of use
WO2025155971A1 (en)	2024-01-19	2025-07-24	Immunomic Therapeutics, Inc	Anti-activin receptor 1c (alk-7) receptor antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9019409D0 (en)	1990-09-05	1990-10-17	Pfizer Ltd	Therapeutic agents
US6235525B1 (en)	1991-05-23	2001-05-22	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en)	1991-05-23	1994-08-30	Ludwig Institute For Cancer Research	Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5405940A (en)	1992-08-31	1995-04-11	Ludwig Institute For Cancer Research	Isolated nonapeptides derived from MAGE genes and uses thereof
CN1118572A (zh)	1993-03-05	1996-03-13	萨依特尔有限公司	Hla-a2.1组合肽及其用途
US5686068A (en)	1994-03-24	1997-11-11	Ludwig Institute For Cancer Research	Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5585461A (en)	1994-03-24	1996-12-17	Ludwig Institute For Cancer Research	Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US5851523A (en)	1994-03-24	1998-12-22	Ludwig Institute For Cancer Research.	Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
ATE347588T1 (de) *	1996-05-23	2006-12-15	Scripps Research Inst	Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US5965535A (en)	1997-09-12	1999-10-12	Ludwig Institute For Cancer Research	Mage-3 peptides presented by HLA class II molecules
EP1064022A4 (de)	1998-03-13	2004-09-29	Epimmune Inc	Hla-bindeproteine und deren verwendung

1998
- 1998-10-05 US US09/166,448 patent/US6291430B1/en not_active Expired - Lifetime
1999
- 1999-09-15 WO PCT/US1999/021230 patent/WO2000020581A1/en not_active Ceased
- 1999-09-15 AT AT99970121T patent/ATE427354T1/de active
- 1999-09-15 DE DE69940671T patent/DE69940671D1/de not_active Expired - Lifetime
- 1999-09-15 AU AU60420/99A patent/AU772720B2/en not_active Ceased
- 1999-09-15 JP JP2000574676A patent/JP4102027B2/ja not_active Expired - Fee Related
- 1999-09-15 EP EP99970121A patent/EP1119623B1/de not_active Expired - Lifetime
2000
- 2000-10-27 US US09/697,884 patent/US6426217B1/en not_active Expired - Lifetime
2002
- 2002-06-12 US US10/170,832 patent/US7252825B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU6042099A (en)	2000-04-26
EP1119623B1 (de)	2009-04-01
JP4102027B2 (ja)	2008-06-18
JP2002526110A (ja)	2002-08-20
WO2000020581A1 (en)	2000-04-13
US6426217B1 (en)	2002-07-30
AU772720B2 (en)	2004-05-06
US20030170792A1 (en)	2003-09-11
US6291430B1 (en)	2001-09-18
EP1119623A1 (de)	2001-08-01
US7252825B2 (en)	2007-08-07
DE69940671D1 (de)	2009-05-14

Legal Events

Date

Code

Title

Description

2009-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1119623

Country of ref document: EP

Publication	Publication Date	Title
ATE427354T1 (de)	2009-04-15	Mage-a3 polypeptide die durch hla-klasse ii molekule prasentiert werden
DE69840868D1 (de)	2009-07-16	Mage-3 peptide, die durch hla-klasse-ii molecule presentiert werden
WO2002095051A3 (en)	2004-02-12	Mage-a3 peptides presented by hla class ii molecules
DK1005540T3 (da)	2004-10-18	IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE295889T1 (de)	2005-06-15	Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
WO2001055308A8 (en)	2001-09-07	Nucleic acids, proteins, and antibodies
EP0796913A3 (de)	2001-01-31	GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
NZ323795A (en)	2000-01-28	Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
DE69637148D1 (de)	2007-08-09	Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
WO2001054472A3 (en)	2002-01-31	Nucleic acids, proteins, and antibodies
WO2001055306A3 (en)	2001-12-20	Nucleic acids, proteins, and antibodies
GR3019849T3 (en)	1996-08-31	Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
DE69935220D1 (de)	2007-04-05	Von menschlichem tumor stammendes polypeptidhormon phosphatonin
IL207012A0 (en)	2011-08-01	Diagnosis and therapy of cancer using sgp28-related molecules
ATE496129T1 (de)	2011-02-15	Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
DE69942637D1 (de)	2010-09-09	Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
WO2002072763A3 (en)	2003-02-27	Nucleic acids, proteins, and antibodies
WO2001055167A8 (en)	2001-12-06	Nucleic acids, proteins, and antibodies
WO2001055162A8 (en)	2001-09-07	Nucleic acids, proteins, and antibodies
WO2001055305A3 (en)	2002-01-24	Nucleic acids, proteins, and antibodies